Q3 FY2026 · ended Sep 30, 2026 · Revenue $7.56M, -41.0% YoY · Filed Nov 3, 2026
Aquestive Therapeutics, Inc. (AQST) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $7.6 million and a net loss of $16.5 million. Free cash flow was -$7.6 million. As of Sep 30, 2026 it held $90.3 million in cash and investments and $63.0 million in total debt.
Revenue
$7.56M
-41.0% vs year-ago quarter
Net income
$-16.50M
-6.8% vs year-ago quarter
Operating cash flow
$-7.05M
+44.3% vs year-ago quarter
Free cash flow
$-7.63M
+40.8% vs year-ago quarter
EPS
$-0.13
+7.1% vs year-ago quarter
Dividend per share
None
Shares outstanding
125.69M
+3.0% vs year-ago quarter
Net cash
$27.37M
Q3 FY2026
Operating margin
-114.1%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AQST (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Warren, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1398733
- Former names
- MonoSol Rx, Inc. (until Mar 27, 2008)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $7.6M | $13.8M | $14.4M | $13.0M | $12.8M |
| Operating income | -$14.5M | -$8.2M | -$4.2M | -$28.8M | -$11.5M |
| Net income | -$16.5M | -$22.9M | -$8.1M | -$31.9M | -$15.4M |
| Diluted EPS | -$0.13 | -$0.18 | -$0.07 | -$0.26 | -$0.14 |
| Operating cash flow | -$7.0M | -$9.4M | -$14.8M | -$8.5M | -$12.6M |
| Free cash flow | -$7.6M | -$9.7M | -$14.9M | -$8.6M | -$12.9M |
| Total assets | $119.3M | $132.1M | $141.1M | $160.4M | $163.6M |
| Total liabilities | $190.2M | $188.7M | $175.2M | $194.1M | $167.7M |
| Stockholders' equity | -$70.8M | -$56.6M | -$34.1M | -$33.7M | -$4.1M |
| Cash and investments | $90.3M | $98.5M | $110.7M | — | $129.1M |
| Total debt | $63.0M | $63.3M | $49.8M | $50.1M | $50.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Nov 5, 2026 | Nov 5, 2026 |
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 3, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Oct 19, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 15, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Material agreement
|
Oct 14, 2026 | Oct 13, 2026 |
All 686 Aquestive Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.